MCID: DRM011
MIFTS: 47

Dermatophytosis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 76 15 73
Tinea 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD10 33 B35 B35.9
ICD9CM 35 110 110.9
NCIt 50 C26745

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea corporis and tinea cruris, and has symptoms including exanthema, fever and pruritus. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways is GPCRs, Class B Secretin-like. The drugs Bifonazole and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include scalp, glabrous skin and nail.

Wikipedia : 76 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 tinea corporis 33.3 DEFB4A SQLE
2 tinea cruris 33.3 DEFB4A SQLE
3 tinea capitis 31.0 CARD9 FLNC KATNAL2 SLC7A1
4 candidiasis 29.8 CARD9 DEFB4A
5 deep dermatophytosis 12.4
6 tinea pedis 11.8
7 tinea unguium 11.6
8 tinea manuum 11.6
9 tinea profunda 11.5
10 tinea barbae 11.4
11 candidiasis, familial, 2 10.8
12 superficial mycosis 10.8
13 dermatomycosis 10.8
14 tinea imbricata 10.4
15 oral candidiasis 10.3 DEFB4A LTF
16 gingivitis 10.1 DEFB4A LTF
17 chronic mucocutaneous candidiasis 9.9
18 opportunistic mycosis 9.9 CARD9 FLNC
19 aging 9.9
20 urticaria 9.9
21 dermatitis 9.9
22 psoriasis 9.9
23 pemphigus 9.9
24 tinea favosa 9.9
25 kerion celsi 9.9
26 erythema multiforme 9.8
27 lymphoma 9.8
28 sarcoma 9.8
29 ichthyosis 9.8
30 congenital ichthyosiform erythroderma 9.8
31 palmoplantar keratosis 9.8
32 acquired immunodeficiency syndrome 9.8
33 ige responsiveness, atopic 9.6
34 kaposi sarcoma 9.6
35 systemic lupus erythematosus 9.6
36 nevus anemicus 9.6
37 rheumatoid arthritis 9.6
38 pituitary adenoma 4, acth-secreting 9.6
39 hemochromatosis, type 1 9.6
40 myasthenia gravis 9.6
41 mycosis fungoides 9.6
42 dermatitis, atopic 9.6
43 langerhans cell histiocytosis 9.6
44 aspergillosis 9.6
45 psoriasis 14, pustular 9.6
46 adult t-cell leukemia 9.6
47 alopecia 9.6
48 arthritis 9.6
49 hepatitis 9.6
50 liver cirrhosis 9.6

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


exanthema, fever, pruritus

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bifonazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60628-96-8 2378
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 5402 1549008
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65277-42-1 47576 3823
6
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29342-05-0 2749
7
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
8
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 73342 47641
9
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
10
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
11
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
12 Gastrointestinal Agents Phase 4,Phase 3
13 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Dermatologic Agents Phase 4,Not Applicable
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antacids Phase 4
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Keratolytic Agents Phase 4,Not Applicable
26 Proton Pump Inhibitors Phase 4
27 Anti-Ulcer Agents Phase 4
28
Hydroxyitraconazole Phase 4,Phase 3,Phase 2
29
Econazole Approved Phase 3,Phase 2 27220-47-9 3198
30
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
31
Clotrimazole Approved, Vet_approved Phase 3,Phase 1 23593-75-1 2812
32
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
33
Griseofulvin Approved, Investigational, Vet_approved Phase 3,Not Applicable 126-07-8 441140
34
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
35
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
38 Papaya Approved, Nutraceutical Phase 2, Phase 3
39 Respiratory System Agents Phase 3,Phase 2
40 Micronutrients Phase 2, Phase 3,Not Applicable
41 Trace Elements Phase 2, Phase 3,Not Applicable
42 Anthelmintics Phase 2, Phase 3
43 Anti-Asthmatic Agents Phase 3,Phase 2
44 Peripheral Nervous System Agents Phase 3,Phase 2
45 Antiparasitic Agents Phase 2, Phase 3,Not Applicable
46 Antiprotozoal Agents Phase 2, Phase 3,Not Applicable
47 Anti-Inflammatory Agents Phase 3,Phase 2
48 Autonomic Agents Phase 3,Phase 2
49 Antimitotic Agents Phase 2, Phase 3
50 Betamethasone Valerate Phase 3 2152-44-5

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
4 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
5 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
6 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
7 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
8 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
9 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
10 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
11 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
12 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl Nail Lacquer;Ciclopirox Nail Lacquer
13 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
14 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl Nail Lacquer;Loceryl Nail Lacquer;Loceryl Nail Lacquer follow up period
15 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
16 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
17 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
18 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
19 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
20 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
21 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
22 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
23 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
24 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
25 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
26 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
27 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
28 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
29 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
30 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
31 Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Completed NCT01349998 Phase 3 Product 33525
32 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
33 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
34 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
35 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
36 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
37 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
38 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
39 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
40 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
41 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
42 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
43 Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
44 A Study Of Diflucan In Children With Ringworm Of The Scalp Completed NCT00645242 Phase 3 fluconazole
45 BE Study of Naftifine HCL Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
46 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
47 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
48 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
49 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
50 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

19
Scalp, Glabrous Skin, Nail

MalaCards organs/tissues related to Dermatophytosis:

41
Skin, Testes, T Cells, Thymus, Monocytes, Lymph Node, Liver

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 630)
# Title Authors Year
1
Evaluation of the value of staining hair samples with a modified Wright-Giemsa stain and/or showing illustrated guidelines for the microscopic diagnosis of dermatophytosis in cats. ( 29664175 )
2018
2
Comparison of real-time PCR with fungal culture for the diagnosis of Microsporum canis dermatophytosis in shelter cats: a field study. ( 29172910 )
2018
3
Landscape of long non-coding RNAs in Trichophyton mentagrophytes-induced rabbit dermatophytosis lesional skin and normal skin. ( 29560532 )
2018
4
Assessment of a pan-dermatophyte nested-PCR compared with conventional methods for direct detection and identification of dermatophytosis agents in animals. ( 29944743 )
2018
5
Is Antifungal Resistance a Cause for Treatment Failure in Dermatophytosis: A Study Focused on Tinea Corporis and Cruris from a Tertiary Centre? ( 29644192 )
2018
6
Emergence of recalcitrant dermatophytosis in India. ( 29485088 )
2018
7
Indian irrational skin creams and steroid-modified dermatophytosis - an unholy nexus and alarming situation. ( 29706004 )
2018
8
Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum. ( 29785830 )
2018
9
Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect? ( 29767491 )
2018
10
Diffuse dermatophytosis occurring on dimethyl fumarate therapy. ( 29649923 )
2018
11
Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis - time to look beyond the MIC data? ( 29243676 )
2018
12
Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. ( 29094463 )
2018
13
Emergence of recalcitrant dermatophytosis in India. ( 29976522 )
2018
14
Erratum: Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics. ( 29657191 )
2018
15
Psoriasiform Dermatophytosis in a Bulgarian Child. ( 29484004 )
2018
16
IL-17-Mediated Immunity Controls SkinA Infection and T Helper 1 Response during Experimental Microsporum canisA Dermatophytosis. ( 29571944 )
2018
17
An invertebrate infection model for evaluating anti-fungal agents against dermatophytosis. ( 28947778 )
2017
18
Comment on: "A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients". ( 28653140 )
2017
19
Use of a commercial qPCR assay in 52 high risk shelter cats for disease identification of dermatophytosis and mycological cure. ( 28833730 )
2017
20
Diagnosis of Dermatophytosis by Conventional Methods and Comparatative analysis of Sabouraud Dextrose Agar and Dermatophyte Test Medium for Isolation of Dermatophytes. ( 28588164 )
2017
21
Isotretinoin may affect pharmacokinetics of itraconazole in the skin: Is it rational to combine both for the treatment of dermatophytosis? ( 27853005 )
2017
22
Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. ( 29323069 )
2017
23
DIAGNOSIS AND SUCCESSFUL TREATMENT OF A POTENTIALLY ZOONOTIC DERMATOPHYTOSIS CAUSED BY MICROSPORUM GYPSEUM IN A ZOO-HOUSED NORTH AMERICAN PORCUPINE (ERETHIZON DORSATUM). ( 28749293 )
2017
24
Topical nitric oxide releasing nanoparticles are effective in a murine model of dermal Trichophyton rubrum dermatophytosis. ( 28712918 )
2017
25
Deep Dermatophytosis Caused by Zoophilic Strain ofA Trichophyton interdigitaleA with Successful Treatment of Itraconazole. ( 28154954 )
2017
26
Dermatophytes and dermatophytosis in the eastern and southern parts of Africa. ( 28419352 )
2017
27
Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD? ( 29263545 )
2017
28
Epidemiological status of dermatophytosis in Guilan, north of Iran. ( 29302626 )
2017
29
Treatment of Dermatophytosis in Elderly, Children, and Pregnant Women. ( 28979861 )
2017
30
Development of enzyme immunoassays (ELISA and Western blot) for the serological diagnosis of dermatophytosis in symptomatic and asymptomatic cats. ( 28340215 )
2017
31
Transcriptome analysis of Trichophyton mentagrophytes-induced rabbit (Oryctolagus cuniculus) dermatophytosis. ( 29225090 )
2017
32
Dermatophytosis: Fighting the Challenge: Conference Proceedings and Learning Points. September 2-3, 2017, PGIMER, Chandigarh, India. ( 29204417 )
2017
33
Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics. ( 28936991 )
2017
34
<i>In Vivo</i> Evaluation of<i>Galla chinensis</i>Solution in the Topical Treatment of Dermatophytosis. ( 29259645 )
2017
35
Trichophyton rubrum tinea capitis in an HIV-positive patient with generalized dermatophytosis. ( 28050591 )
2017
36
Clinical evaluation of I^-tubulin real-time PCR for rapid diagnosis of dermatophytosis, a comparison with mycological methods. ( 28699277 )
2017
37
A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients. ( 28389891 )
2017
38
Phytochemical analysis and docking study of compounds present in a polyherbal preparation used in the treatment of dermatophytosis. ( 29707673 )
2017
39
Diagnosis and treatment of dermatophytosis in dogs and cats.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. ( 28516493 )
2017
40
Cellular immunodeficiency related to chronic dermatophytosis in a patient with Schistosoma mansoni infection: can schistosomiasis induce immunodeficiency? ( 28327819 )
2017
41
Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis. ( 28794551 )
2017
42
The Great Indian Epidemic of Superficial Dermatophytosis: An Appraisal. ( 28584364 )
2017
43
Relationship Between Phenotypic and Genotypic Characteristics of Trichophyton mentagrophytes Strains Isolated from Patients with Dermatophytosis. ( 28101694 )
2017
44
Correlation between histopathologic features and likelihood of identifying superficial dermatophytosis with periodic acid Schiff-diastase staining: a cohort study. ( 27859475 )
2017
45
The menace of dermatophytosis in India: The evidence that we need. ( 28366915 )
2017
46
Dermatophytosis: fluorostaining enhances speed and sensitivity in direct microscopy of skin, nail and hair specimens from dermatology outpatients. ( 26931645 )
2016
47
Modeling dermatophytosis in reconstructed human epidermis: A new tool to study infection mechanisms and to test antifungal agents. ( 27760830 )
2016
48
Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. ( 27780596 )
2016
49
Dermatophytosis among Schoolchildren in Three Eco-climatic Zones of Mali. ( 27124571 )
2016
50
Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis. ( 26720159 )
2016

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

Pathways related to Dermatophytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10 ADGRL1 ADGRL2

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antimicrobial humoral response GO:0019730 9.16 DEFB4A LTF
2 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 8.96 DEFB4A LTF
3 killing of cells of other organism GO:0031640 8.62 DEFB4A LTF

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 latrotoxin receptor activity GO:0016524 8.62 ADGRL1 ADGRL2

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....